Putting genes to the test

As new technologies fill the landscape of molecular diagnostics, two fault lines are becoming clear: next-generation sequencing versus PCR, and tumor biopsies versus ctDNA. But while stakeholders believe there’s room for it all, they warn that lack of data-sharing could undermine the field’s ability to deliver on expectations for precision medicine.

The divisions separate emerging technologies from the more traditional methods in genome-based diagnosis and drug development. ...